Department: Medical & Regulatory, Novo Nordisk Malaysia
Location: Kuala Lumpur, Malaysia
As Medical Scientific Liaison, you will be the scientific expert in the field for our Cardiometabolic portfolio in Malaysia. You will turn medical affairs strategy into meaningful engagement with key opinion leaders (KOLs) and healthcare professionals (HCPs), sharing evidence, building advocacy and raising disease awareness. The insights you bring back will shape how our teams support HCPs – and how people living with cardiometabolic diseases are cared for in real life, today.
You are a medical or scientific professional who enjoys translating evidence into conversations that change practice. You will bring:
You will own the execution of the local medical affairs and field medical affairs strategy, with a strong focus on external KOL engagement and advocacy, while acting as a trusted scientific resource for colleagues.
You will join the Medical & Regulatory department in Malaysia, a key function that enables the business strategy through effective execution in Medical Affairs and Regulatory. The team ensures regulatory compliance for new products and product amendments, safeguards patient safety and maintains our licence to operate.
You will report directly to the Medical Scientific Liaison Manager and share monthly engagement and KOL reports with the Medical Advisor. Internally, you will work closely with sales, marketing, safety and other in-field and commercial colleagues, sharing what you learn from customers so engagement stays consistent and valuable. Externally, your closest partners will be KOLs, HCPs and investigators across Malaysia.
Around 80-90% of your time will be spent in the field, where your conversations help turn insights into joint actions and keep the work moving forward.
This is a full-time, permanent position where you are trusted to own your area and make your voice heard. You will build new skills across scientific communication, customer engagement and cross-functional collaboration, working with both medical and commercial teams. You will be encouraged to stay curious, try new approaches to customer engagement and learn from the world outside Novo Nordisk – and you will be supported to perform at your best while doing it.
Your impact begins today. If you are ready to bring science to life for HCPs and help create progress for people living with cardiometabolic diseases in Malaysia, apply for the Medical Scientific Liaison role by 26 October 2026.
We commit to an inclusive recruitment process and equality of opportunity for all our job applicants.

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health.
Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com.
This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.
Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in:
https://www.novonordisk.com/contact-us/find-local-information.html
For other customer complaints, please contact us here:
https://www.novonordisk.com/contact-us.html
Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed.
Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.
Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html